Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Abstract Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemis...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2017-04-01
Serija:	Genome Medicine
Teme:	Tumor mutational burden Cancer genomics Mismatch repair PMS2
Online dostop:	http://link.springer.com/article/10.1186/s13073-017-0424-2
Oznake:	Označite Brez oznak, prvi označite!